Offidani Emanuela, Fava Giovanni A, Sonino Nicoletta
Center for Complementary and Integrative Medicine, Weill Cornell Medical College, New York, NY, USA.
CNS Drugs. 2014 Sep;28(9):769-74. doi: 10.1007/s40263-014-0184-0.
The term "iatrogenic comorbidity" refers to unfavorable modifications in the course of an illness, with regard to its characteristics and responsiveness, which may be related to previous treatments. Some iatrogenic adverse events arising from either pharmacotherapy or psychotherapy cannot be subsumed under the traditional rubric of adverse effects and require careful evaluation. Children and adolescents are generally more likely to experience adverse health consequences after drug treatment. The use of antidepressant drugs in this age group may cause potential long-term detrimental effects, such as mood elevation that does not subside when drugs are discontinued and may predispose to the development of a bipolar disorder. The concept of iatrogenic comorbidity in children and adolescents has heuristic value in weighing potential benefits and risks associated particularly with psychotropic treatments.
“医源性共病”一词指的是疾病过程中在其特征和反应性方面出现的不良改变，这可能与先前的治疗有关。一些由药物治疗或心理治疗引起的医源性不良事件不能归入传统的不良反应类别，需要仔细评估。儿童和青少年在药物治疗后通常更容易出现不良健康后果。在这个年龄组使用抗抑郁药物可能会导致潜在的长期有害影响，例如停药后情绪升高仍不消退，并且可能易患双相情感障碍。儿童和青少年医源性共病的概念在权衡潜在益处和风险时具有启发价值，尤其是与精神药物治疗相关的风险。
